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Excimer Laser Trabeculostomy (EL T): 
An Effective MIGS Procedure 
for Open-Angle Glaucoma 
Michael S. Berlin, Mare Töteberg-Harms, Edward Kim, 
Iris Vuong, and Ulrich Giers 
Elevated intraocular pressure (IOP) in most open-angle glau-
coma is due to an obstruction of aqueous outftow thought to 
be localized predorninantly at the juxtacanalicular trabecular 
meshwork (TM) and the inner wall of Schlemm's canal (SC). 
There have been multiple surgical attempts to directly treat 
this pathology by creating channels to connect the anterior 
chamber to SC. Various iterations have included mechanical 
drilling techniques, thermal Iaser and alternative thermal 
cautery techniques, and a variety of tube implants with the 
common goal of bypassing this increased outftow resistance. 
However, the majority of these techniques concurrently or 
subsequently create sufficient adjacent tissue disruption to 
eventuate in inftammatory healing responses adequate to 
overcome the benefits of the procedures, resulting in rnid-
term or long-term failures. To overcome these known causes 
of failure, technologies and techniques for the purpose of 
creating such channels were sought which did not cause scar 
tissue formation. The requirements include minimal tissue 
disruption during the process of creating the openings and 
channels which are of adequate size and number to enable 
outftow but not so large as to alter the aqueous composition. 
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The excimer Iaser trabeculostomy (ELT) concept utilizes a 
308-nm xenon chloride excimer Iaser to provide a precise and 
essentially nonthermal approach to improve outftow in a man-
ner which does not provoke a healing response. ELT is a pro-
cedure performed via a clear corneal incision, sparing 
conjunctiva, in which direct visualization of the target tissue 
via a goniolens or an endoscope provides immediate feedback 
to the surgeon. ELT, when compared to the more invasive 
glaucoma surgical procedures such as trabeculectomy, is 
almost as efficacious in both IOP-lowering and decreasing 
pressure-lowering medication use, while being far less trau-
matic. The sparing of conjunctiva is a major advantage of this 
technique, because success rates of a subsequent trabeculec-
tomy, if ever necessary, would not be comprornised. This 
rnicroinvasive glaucoma surgery (MIGS) procedure, another 
option in the armamentarium for the glaucoma surgeon, has a 
high safety profile, rapid stabilization, and clinical verifica-
tion of long-term efficacy with minimal impact on quality of 
life. It may also become a replacement option for topical glau-
coma medicinal therapies eliminating their associated cost, 
compliance issues, and side effects from their long-term use. 
What Are MIGS Procedures and Where Do 
They Fit in Glaucoma Treatment Paradigms? 
The invasive procedure and Iifestyle altering sequelae of tra-
beculectomy Iimit the use of this procedure to later stage and 
recalcitrant glaucoma patients. Issues regarding medication 
costs, compliance, and toxicity of preservatives suggest 
medicinal therapeutic options also have lirnitations. Thus, 
there remains an unmet patient need for treatments that could 
effectively treat mild to moderate glaucoma. In recent years, 
several MIGS procedures have been developed to address 
these limitations of traditional treatment options. All have 
advantages and disadvantages, but no current technique ful-
fills all requirements which are (1) ab interno rnicroincision, 
(2) minimal trauma, (3) efficacy, (4) high safety profile, and 
(5) rapid recovery [1]. 
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1. MIGS procedures use an ab interno micro-incisional 
approach through a clear corneal incision of less than 
2 mm, which spares the conjunctiva and thus prevents 
significant external scarring, allowing future unaffected 
conjunctival surgery, if needed. This also allows for direct 
visualization of anatomic Iandmarks to optimize place-
ment of a device, incision or excision within the angle and 
is easily combined with cataract surgery. Furthermore, a 
micro-incision facilitates the intra-operative maintenance 
of the anterior chamber, retention of normal ocular anat-
omy, minimizes changes in refractive outcome, and adds 
to procedural safety. 
2. MIGS procedures are minimally traumatic to the target 
tissue, with negligible disruption of normal anatomy and 
physiology. Devices are biocompatible and ideally 
enhance physiologic outftow pathways. 
3. MIGS procedures must be effective in both lowering IOP 
and reducing medication use. 
4. MIGS procedures are characterized by an extremely high 
safety profile. Many MIGS procedures are less effica-
cious when compared to more invasive glaucoma surger-
ies such as trabeculectomy with antimetabolites or 
glaucoma drainage devices. However, this compromise in 
efficacy is balanced by their low-risk profile. MIGS pro-
cedures are associated with a decreased incidence of seri-
ous complications that are often associated with other 
glaucoma surgeries including hypotony, choroidal effu-
sions, suprachoroidal hemorrhage, anterior chamber shal-
lowing, corneal decompensation, cataract formation, 
diplopia, and bleb-related complications such as bleb 
dysesthesia and endophthalmitis. 
5. MIGS procedures have a rapid recovery with minimal 
impact on the patient' s quality of life. 
In conclusion, MIGS procedures fit for mild do moderate 
glaucoma cases, in which an IOP in low to mid teens is suf-
ficient. In addition, a reduction in IOP lowering medication 
is desired. The safety profile of the procedure as weil as a 
rapid recovery is important. 
Previous Meshwork Surgeries 
and Their Disadvantages 
Current MIGS procedures can successfully bypass the TM in 
order to create direct ftow from the anterior chamber into SC 
unlike earlier attempts to address this anatomic pathology, 
which often failed. Procedures utilizing mechanical devices 
and Iasers to perforate the TM have been shown to ade-
quately bypass the outftow obstruction for the short term but 
have been unsuccessful in the long term due to the amount of 
adjacent tissue darnage related to the nature of the technique 
or device. The adjacent tissue darnage evokes a healing 
response which eventually closes the channels. As Iaser tech-
nology evolved, each new Iaser was applied for this purpose, 
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but none enabled long-term patent openings. Krasnov et al. 
showed moderate success using a ruby Iaser (943 nm) to per-
form "trabeculopuncture" [2]. Other Iaser trabeculopuncture 
attempts including Hager's [3] use of an argon Iaser 
(488+514 nm) and Fankhauser's [4] use of a neody-
mium:yttrium-aluminum-garnet (Nd:YAG) Iaser (continu-
ous wave 1,064 nm) have also been unsuccessful due to 
scarring. These and other Iaser trabeculopuncture attempts 
also Iimit prospective options for subsequent procedures 
[5, 6] should they become necessary as they induce destruc-
tion of local tissue and scar formation of adjacent tissue, 
often involving large regional areas. In addition, with large 
openings and markedly increased outftow, the compositional 
alterations of the aqueous would Supplement the tissue 
destructive healing responses. 
Following these initial attempts using Iasers ab interno to 
perforate TM or to create full-thickness sclerostomies, Wise 
et al. determined that a continuous wave, essentially long 
pulsed argon Iaser (488+514 nm) could successfully modify 
the TM to increase outftow without perforation. Their argon 
Iaser trabeculoplasty (ALT) procedure effectively lowered 
IOP, but it functioned by creating thermal darnage to the tar-
get tissue, causing coagulative necrosis of the TM [7]. In 
contrast to ALT, Iaser trabeculoplasty (LTP) is now more 
commonly performed with solid-state (532, frequency-
doubled Nd:YAG) and diode (810 nm) Iasers. Studies com-
paring efficacy of these thermallasers demonstrate minimal 
differences in efficacy, longevity, or repeatability. 
The efficacy of LTP in lowering IOP has been weil docu-
mented in the Iiterature [8-10]. However, long-term studies 
have shown that the IOP-lowering efficacy of LTP decreases 
over time, from 77 % success rate at 1 year, to 49 % at 
5 years, and finally, to 32 % at 10 years [11]. Additionally, 
because of the significant TM scarring caused by ALT, repeat 
treatments are not recommended and have not proven suc-
cessful clinically [12]. LTP causes thermal coagulative darn-
age to the uveoscleral meshwork, disruption of the trabecular 
beams, and heat darnage to the surrounding collagen fibers. 
This thermal darnage is in part responsible for the inflamma-
tory response, scarring of the TM tissue, peripheral anterior 
synechiae, and IOP spikes sometimes observed in eyes 
which have undergone LTP [13] . 
In cantrast to the diffuse thermal effects of argon, solid-
state, and diode Iaser with relatively long pulse durations in 
the range of 0.1 s, recent advances in LTP utilize Iasers with 
shorter pulse durations of 3-10 ns. Selective Iaser trabeculo-
plasty (SLT), based on the principle of selective photother-
molysis, relies on selective absorption of short Iaser pulses to 
generate and spatially confine heat to pigmented targets 
within TM cells [14, 15]. SLT uses a Q-switched, frequency-
doubled 532-nm Nd:YAG Iaser. Q-switching of the Iaser 
allows for an extremely brief and thus high-powered light 
pulse to be delivered to the target tissues. The short duration 
of the pulse is critical in preventing collateral darnage to the 
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surrounding tissues [16]. The mechanisms of the pressure 
effects following ALT, LTP, and SLT which alter but do not 
perforate TM are yet undeterrnined. 
Preserving the TM may become more important in the 
near future, as surgical techniques are developed to operate 
directly on SC or the juxtacanalicular TM. Thermal LTP 
would preclude the use of the newer MIGS procedures in 
thes~ patients, as their TM and adjacent tissues, including SC 
would be likely to have been damaged. Once methods ofpre-
operative evaluations of the patency of the required outfiow 
pathways are clinically useful, such patients can be better 
evaluated as candidates for MIGS procedures. 
The Concept of EL T 
Ultraviolet excimer laser photoablation enables the precise 
removal of targeted tissue with meticulous local and adjacent 
temperature control to prevent thermal darnage to surrounding 
tissues, exemplified by the use of 193-nm excimer lasers for 
comeal surface ablation, which facilitates successful refractive 
surgery. However, the 193-nm wavelength, although precise and 
non-tissue darnaging, is not readily transmissible via fiber optics 
and can therefore not be used for intracarneral procedures. In 
contrast, 308-nm excimer laser generated light is arnenable to 
fiber-optic transmission and, after extensive preclinical experi-
mentation, becarne the wavelength of choice for non-thermal, 
precisely targeted ab intemo fistulizing procedures [17]. The 
applications ofthis non-thermal, ab intemo, fiber-optic-delivered 
energy evolved, initially from full-thickness sclerostomy, creat-
ing a bleb via an ab intemo approach, subsequently to trabeculos-
tomy, once the pararneters of the target tissue anatomy' [18, 19], 
localization of SC, and ablation rates for this wavelength in this 
tissue were deterrnined and idealized to enable a successful 
procedure to bypass TM and juxtacanalicular TM obstructions 
allowing and improving physiological outfiow directly into SC. 
Initial in vitro experiments led to animal trials [20]. In a 
study of the effects of 308-nm excimer laser energy applied ab 
intemo to the limbal sclera of rabbit eyes, long-term decreases 
in IOP were achievable. The use of this 308-nm wavelength, 
unlike that of earlier trials with thermallasers, enables laser-
tissue interactions with significant advantages. This excimer 
1Target tissue anatomic considerations to minimize healing responses 
must specifically address minimizing trauma to the outer wall of SC. 
The outer wall endothelium contains fibroblasts , whereas the inner wall 
endothelium does not. Thus, avoiding trauma to the outer wall and 
thereby not stimulating a fibroblast response is paramount to the suc-
cessful maintenance of outflow. Another anatomic consideration is the 
space between the inner and outer walls of SC, which can be less than 
20 11m. The accuracy of the tool used to enter the inner wall such that it 
does not disturb the outer wall must be of this same scale. The ablation 
precision of 308 nm on this tissue, unlike that of Iasers and devices 
utilized in earlier attempts to fistulize SC, facilitates the non-thermal 
and accurate tissue removal which thereby enables the ELT procedure's 
efficacy. 
laser is less likely to evoke a cicatricle response in the TM or 
sclera than those seen in trials using visible or infrared lasers, 
which cause thermal tissue darnage and subsequent healing 
responses. In addition, there is minimal exposure of adjacent 
tissue to radiation enabled by direct contact of the laser energy 
to the target tissue via the fiber-optic delivery system. With 
evidence that TM and scleral tissue could be successfully 
removed without adjacent tissue damage, without subsequent 
scar formation or channel closure, and with ablation accuracy 
which would enable precise targeting of TM, juxtacanalicular 
TM, and the inner wall of SC without perforating the outer 
wall of SC, these studies formed the basis for the development 
ofthe current ELT technology and techniques [21]. 
ELTTechnique 
ELT, first used clinically in 1997 by Vogel and Lauritzen, 
treats the pathology responsible for most open-angle glau-
coma by decreasing the outfiow resistance at the juxtacana-
licular TM and the inner wall of SC [22]. It is performed with 
a short-pulsed (80 ns) 308-nm xenon chloride (XeCl) excimer 
laser which delivers photoablative energy to precisely remove 
the tissue which obstructs aqueous outfiow with minimal ther-
mal darnage to adjacent tissue [23]. ELT surgery is performed 
as an outpatient procedure, under topical, peribulbar, or retro-
bulbar local anesthesia. Following a paracentesis and stabili-
zation of the anterior charnber with a viscoelastic agent, the 
surgeon introduces a fiber-optic probe, which is advanced 
across the anteriorcharnberto contact the TM (Fig. 8.1). Probe 
placement is controlled by direct observation using either a 
goniolens or an endoscope. Four to ten channels are created 
into SC (Fig. 8.2). The probe is then removed, the viscoelastic 
agent is replaced by balanced salt solution, and the patient is 
monitored postoperatively. Most comrnonly the probe inser-
tion is superotemporal and the laser channels inferonasal. 
Variations include spacing the channels over both inferior 
quadrants, creating temporary hypotony following removal of 
the probe to enable enumeration of the number of patent chan-
nels into SC by observing an induced retrograde blood refiux 
followed by repressurization, arnong others. The blood refiux 
is a comrnon but inconsequential occurrence (Fig. 8.3). To 
date no studies have shown benefit from treatment in more 
than one quadrant. As no single protocol has been established, 
each surgeon tends to create their own technique. In spite of 
these numerous variations, the outcomes are remarkably 
similar. 
By means of the essentially non-thermal photoablation 
using the specified laser parameters, ELT evaporates human 
tissue, denaturing the organic structures without producing 
undesirable marginal necrosis [24] . ELT excises the TM, the 
juxtacanalicular TM, and the inner wall of SC without darn-
aging the outer wall of SC or the collector channels [25]. No 
filtering fistula or bleb is created [21, 26, 27]. 
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Fig. 8.1 Drawings and photos of the excimer Iaser trabeculostomy 
procedure. The Iaser fiber is introduced into the anterior chamber 
through a clear cornea incision (a) and advanced across the anterior 
chamber (b) to the trabecular meshwork of the opposite quadrant (c). 
When the fiber tip is in contact with or slightly compresasing the 
Technical Aspects of Performing 
an EL T Procedure 
The current ELT procedure is performed with an AIDA XeCl 
laser (TUI-Laser AG, Germering, Germany) in the following 
M.S. Berlin et al. 
trabecular meshwork Iaser pulses are initiated (d). Tissue fluorescence 
produced by each UV Iaser pulse can be visualized gonioscopicly (e). A 
series of Iaser channels of approx. 0.2mm diameter each enabels flow 
from the anterior chamber to Schlemm's canal (f) . a , c-d, and f : Peschke 
GmbH, Waldshut-Tiengen, Germany; band e: U. Giers 
1. The laser is automated to internally calibrate and con-
trol the output fluence in accordance with the manu-
facturer's specifications. Unlike solid-state lasers, 
this XeCl gas laser requires a short "warm up" time 
during which the output energy is stabilized before 
Fig. 8.2 Gonioscope view!IOP high=SC not visible (U. Giers) 
Fig. 8.3 Endoscopic view/IOP low=SC visible, blood filled (U. Giers) 
2. The sterile, non-reusable fiber-optic delivery system is 
coupled to the Iaser. The output beam is then adjusted at 
the fiber tip to ensure suprathreshold ftuence for tissue 
ablation at the fiber tip. The console includes a power 
meter to enable this calibration which is performed prior 
to each procedure, similar to the tuning of a phaco hand-
piece before use. 
3. Topical, peribulbar, or retrobulbar local anesthesia is 
administered. In ELT alone, topical pilocarpine 2 % is 
used preoperatively to constrict the pupil. In phakic 
patients this may also assist in protecting the lens. 
Alternatively, intracameral Miochol (acetylcholine 
10 mg/ml) may be used. 
Fig. 8.4 Paracentesis in the superotemporal perilimbal cornea 
(U. Giers) 
Fig. 8.5 Viscoelastic agent is introduced (U. Giers) 
4. A 1 mm paracentesis is created in the superotemporal per-
ilimbal cornea 2 o'clock for left eyes and 10 o'clock for 
right eyes, or in combined cataract and ELT procedures, 
the previously created phaco-tunnel may be used in a sim-
ilar fashion (Fig. 8.4). 
5. A viscoelastic agent (Healon) fills the anterior chamber 
through the paracentesis. Depending on the surgeons' 
preference, the IOP may be unchanged or increased by 
this injection, enabling or precluding visualization of SC 
by blood reftux (Fig. 8.5). 
6. The Iaser probe is inserted into the anterior chamber 
through the paracentesis (Fig. 8.6) and is advanced to the 
opposite chamber angle via gonioscopic (using the sur-
geon's preferred goniolens) or endoscopic visualization 
(Fig. 8.7). The ELT fiber may be attached coaxial with an 
endoscope, or a second paracentesis endoscopic view 
may be utilized. 
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Fig. 8.6 Laser probe is inserted through the paracentesis to cross the 
anterior chamber (U. Giers) 
7. The fiber tip is centered on the pigmented TM and 
advanced to be in contact with the TM. SC is targeted 
whenever visible, or surgeons are advised to alternate 
placement of the fiber to anterior, mid, and posterior TM 
regions to assure some of the channels will, in fact, enter 
into SC. The number of pulses which controls the pene-
tration depth is fixed, similar to the penetration depth 
control in LASIK. Perforation of the inner wall of SC into 
SC depends, therefore, on its distance from the fiber tip 
which can be variable depending on the angle of place-
ment and the amount of pressure on the fiber. The calcula-
tion of this distance was determined in numerous 
preclinical experiments [28, 29]. Thus, the most common 
protocol consists of ten probe placement sites on TM, a 
percentage of which is likely to enter SC. 
8. The Iaser is activated, delivering Iaser pulses at 20 Hz 
per treatment site. Each pulse converts the tissue at the 
fiber tip into gas. This gas may be seen exiting araund 
the fiber tip during each ablation (Fig. 8.8). 
9. As the channel is created, pulse by pulse, an opening is 
created from the anterior chamber into SC through pho-
toablation of the TM, the juxtacanalicular TM and the 
inner wall of SC. As soon as the outftow obstruction at 
the fiber tip is removed as SC is entered, the pathway for 
the gas, previously retrograde araund the fiber, becomes 
anterograde, entering SC. In theory, this product-of-
ablation gas is then assumed to dilate SC, pushing the 
outer wall away and concurrently dilating the adjacent 
surrounding collector channels. This concept of the 
product-of-ablation gas dilation of SC and collector 
channels is termed "pneumatic canaloplasty." Once ade-
quate imaging devices are developed to visualize this 
process in real time, this theory can be validated. 
10. The probe tip is then repositioned such that additional 
channels are created. 
M.S. Berlin et al. 
Fig. 8.7 (a) Gonioscopi t view ofELT probe in contact with TM (white 
arrow). (b) Blood in Schlemm's canal (arrow) verifies appropriate tar-
geting and depth, gonioscopic view (c) Induced blood reflux verifies 
success and enables documentation of number of successful channels 
into Schlemm's canal (U. Giers) 
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Fig. 8.8 In this series of chanels created tissue fluorescence is visible 
during a UV Iaser pulses creating the next channel. (U. Giers) 
Fig. 8.9 Viscoelastic is exchanged for BSS (U. Giers) 
11. The probe is removed from the anterior chamber. 
12. The viscoelastic agent is exchanged for BSS with irriga-
tion/aspiration, coaxial or bimanual (Fig. 8.9). 
13. The anterior chamber can be monitored for the number 
of and location of patent trabeculostomy sites by blood 
reftux from SC during a period of iatrogenic temporary 
hypotony during the viscoelastic agent/fluid exchange. 
Postoperative topical ophthalrnic medication regimens 
are individualized by surgeon, most include: 
1. A combination of steroid and antibiotic eye drops or oint-
ment is administered immediately at the end of the 
procedure. 
2. The operated eye is shielded or patched, and the patient is 
released once stable, sirnilar to after phacoemulsification. 
3. The operated eye is usually treated with a topical fixed com-
bination of steroid (dexamethasone 0.1 %) and antibiotic 
eye drops qid for 1 week and then tapered over 3 weeks. 
Fig. 8.10 Patent trabeculostomy channels into SC (arrow) documented 
2.5 years after ELT (U. Giers) 
4. In the rare case of an anterior chamber inftammatory 
reaction, mydriatic eye drops may be added and the topi-
cal steroid can be intensified by surgeon's preference. 
Most surgeons discontinue all antiglaucoma medica-
tions after the procedure. However, prooperative antiglaucoma 
medication may be continued and later reduced dependent 
on the postoperative IOP. When medications are reduced, 
IOP should be monitored carefully on a regular basis. 
AfterELT 
ldeally, the patients are monitored postoperatively with goni-
oscopy in addition to IOP and the findings documented as to 
the number of sites noted patent. In the cases that have been 
followed in this manner, channels are documented to remain 
patent years after the ELT procedure, and in some of these 
patients, goniolens "pumping" can induce blood to appear at 
the channels, further confirming the patency of these 
channels into SC (Figs. 8.10 and 8.11). 
EL T Enables Pneumatic Canaloplasty 
Another potential benefit of ELT is that it enables pneumatic 
canaloplasty. Both endoscopic and gonioscopic views of ELT 
have revealed gas bubble formation in the tissue and in the 
anterior chamber as a result of photoablation of the TM tis-
sue. When the ablation penetrates the outftow obstruction, 
gas is able to enter SC through the newly formed openings in 
the TM. The pressure of this gas has been proposed to local-
ized dilate SC and collector channels to improve aqueous 
outftow, thereby lowering IOP. Observing gas bubbles exiting 
the adjacent openings confirms continuity of ftow from SC. 
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Fig. 8.11 Blood Reflux at the patent opening of a Iaser channel (white 
arrow) from SC induced by "pumping" the goniolens 3 years after ELT 
(U. Giers) 
This hypothesis has yet to be confirmed via real-time 
imaging or histologic studies. Real-time imaging and post-
martern histologic studies - in addition to histologic studies 
after ELT to evaluate the long-term changes which occur 
subsequent to this procedure- will enable better understanding 
of the effects and effectiveness of the current procedure and 
enable suggestions for modifications to potentially further 
improve the outcomes (Fig. 8.12). 
EL T as a MIGS Procedure 
To date the study with the largest sample size was published in 
2006 by Pache et al. [30]; included were 135 eyes with open-
angle glaucoma or ocular hypertension after ELT alone or ELT 
combined with phacoemulsification. The follow-up was 1 
year. Separately two subgroups (subgroup 1 with IOP 
>22 mmHg at baselirre and subgroup 2 with IOP ~21 mmHg 
at baseline) were analyzed. Success (IOP ~21 mmHg, 20 % 
reduction from baseline, antiglaucoma medications (AGM) ~ 
baseline, and no subsequent IOP-lowering surgery) was for 
ELT alone in SG157% (baseline IOP: 27.9±3.9 mmHg; IOP 
at 1 year f/u: 19.3±5.5 mmHg) andin SG2 41 % (baseline 
IOP: 20.2±1.1 mmHg; IOP at 1 year f/u: 17.6±3.3 mmHg) 
and for ELT combined with phacoemulsification, in SG 1 91 % 
(baseline IOP: 26.4±2.8 mmHg; IOP at 1 year f/u: 
M.S. Berlin et al. 
16.7±2.8 mmHg) and in SG2 52 % (baseline IOP: 
19.6± 1.1 mmHg; IOP at 1 yearf/u: 16.3±2.2 mmHg). Hence, 
IOP reduction by ELT appears to be effective in both groups, 
but much more effective in eyes with higher baselirre IOP. This 
finding has beerr confirmed by a later study [31]. 
Wilmsmeyer et al. investigated the outcome after ELT 
alone (70 eyes) versus ELT combined with phacoemulsification 
(60 eyes) after a follow-up of 2 years in patients with open-
angle glaucoma or ocular hypertension [32]. They found a 
higher reduction of IOP after the combined procedure (IOP 
reduced from 24.1 ± 0. 7 mmHg to 16.8 ± 1.0 mmHg at 2 
years after ELT alone vs. reduced from 22.4±0.6 mmHg to 
12.6± 1.5 at 2 years after combined ELT. AGM use did not 
significantly change). 
Babighian et al. found comparable results in an ELT study 
with 2 years follow-up of 21 eyes with open-angle glaucoma 
[33]. Success (IOP decrease 20%with no additional medica-
tion, or IOP-lowering surgery) rates were 54% and IOP was 
reduced from 24.8 ± 2.0 mmHg at baselirre by 7.9 ± 0.1 mmHg 
at 2 years. 
Töteberg-Harms et al. were the first to showsimultaneaus 
IOP reduction and reduction of antiglaucoma medication after 
combined ELT (IOP changed from 25.33±2.85 at baselirre to 
16.54±4.95 at 1 year, while medications were reduced from 
2.25 ± 1.26 at baselirre to 1.46± 1.38 at 1 year) [34]. Complete 
success (IOP <21 mmHg, IOP reduction ~20 %, without anti-
glaucoma medications, and no subsequent IOP-lowering sur-
gery) in their study population was 21.4 % and qualified 
success (same as complete success but additional antiglau-
coma medications were not excluded) 64.3 % at 1 year. 
Berlin et al. investigated 46 eyes after combined ELT with 
a follow-up of 5 years [35]. They showed that IOP was low-
ered (from 25.5 ± 6.3 at baselirre to 15.9 ± 3.0 at 5 years) and 
antiglaucoma medications were reduced (from 1.93 ± 0.87 at 
baselirre to 0.93 ± 1.12 at 5 years) and that this effect remairred 
stable over the entire follow-up of 5 years. 
In conclusion, currently published data demonstrates that 
ELT can reduce IOP and lower antiglaucoma medication 
simultaneously for up to 5 years. The combined procedure, 
ELT plus phacoemulsification, appears to be more effective 
than ELT alone, and the amount of IOP lowering seems tobe 
dependent on baselirre IOP and is more effective in eyes with 
higher baselirre IOP. 
ELT has shown favorable outcomes in comparison to 
other outflow procedures (Fig. 8.13). Although ELT, as a 
laser treatment for glaucoma, is likely to be considered with 
other glaucoma laser treatments, it is not at all comparable in 
laser/tissue interaction effects. When compared to office 
laser treatments, patients undergoing SLT achieved up to a 
27 % postoperative decrease in IOP but a negligible decrease 
in medications. Patients undergoing ALT had similar results, 
with a maximum of 23.5 % postoperative decrease in IOP 
and negligible decreases in medications. 
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Fig. 8.12 Photos of the ELT procedure demonstrating pneumatic canaloplasty: (a) Co axial endoscopic view. (b) As the second channel is created 
into SC, (c) bubble expansion is observed at the first ELT site confirming channel patency into SC at both sites (J. Funk, Zurich, Switzerland) 
ELT as an invasive surgical procedure has also shown 
favorable outcomes when compared to studies of other 
MIGS procedures. Patients undergoing clear cornea phaco-
emulsification followed by ab interno gonioscopically 
guided implantation of one iStent® achieved an IOP decrease 
of 21.4 % and a medication decrease of 75 % 1 year postop-
erative. Patients undergoing phacoemulsification cataract 
extraction combined with Trabectome achieved IOP 
decreases of up to 31 .1 % and medication decreases of 
41.7 %. 
Of most relevance is the finding that ELT has shown 
comparable long-term IOP-lowering results (decrease of 
38.6 % after 5 years) to significantly more invasive and risk 
inherent traditional OR surgeries, trabeculectomy and tube 
shunt procedures. Though trabeculectomy has demonstrated 
IOP decreases of 57.1 % and medication decreases of up to 
90 %, when comparing the data obtained in the Collaborative 
Initial ·Glaucoma Treatment Study (CIGTS) on trabeculec-
tomy patients, the 5-year postoperative ELT intraocular pres-
sure measurements at all time points averaged 1 mm higher 
than those in the 300 patients who underwent trabeculec-
tomy documented in CIGTS. In addition, the intraoperative 
complication rate of trabeculectomy was 12 %, and the 1 
month postoperative complication rate was 50 % versus ELT 







Ber11net i i.,GIBH2013 
Fig. 8.13 Comparison of various outflow procedures based on the 
results of exemplary studies.35-44 
Limitations and Next Generation 
Feedback from leading surgeons who have performed over 
2,000 ELT procedures have identified several limitations of 
the current ELT technique. The next generation of devices, 
called Guided ELT, is currently under development and is 
aimed to address the feedback from reporting surgeons. New 
sensors are being produced to better enable the surgeon to 
locate SC and TM and to automate the control of the Iaser, 
whereas currently tactile contact under observation provides 
surgeon feedback as to the amount of pressure applied to the 
meshwork. Furthermore, additional system controls assist in 
guiding the surgeon as to the depth of tissue removal and 
number of Iaser pulses required to penetrate the inner wall of 
SC with automated detectors and with imaging, especially 
real-time imaging. The progression of spectral-domain opti-
cal coherence tomography development in recent years 
shows promising abilities to meet these needs. 
Conclusion 
ELT is a safe and effective method to reduce both IOP and 
medication use with minimal complications in most 
patients with open-angle glaucoma. lt is less invasive rela-
tive to the methodologies currently being practiced and 
thus reduces many postoperative issues, including patient 
discomfort, number of postoperative visits required to 
assure adequacy and stability, and especially the long-term 
risks of filtering procedures. B y essentially eliminating the 
damaging and healing response inducing thermal effects 
and tissue trauma seen with other Iaser and device proce-
dures, ELT enables the lowering of IOP on a long-term 
basis. Furthermore, due to the minimal tissue trauma asso-
ciated with UV tissue photoablation, only a few, small 
channels into SC have proven adequate to control the IOP. 
Unlike trabeculectomy, ELT preserves the integrity of the 
meshwork and SC, which restores the natural outftow 
without the creation of blebs or invasive foreign body 
implants. ELT is an important adjunct to cataract surgery, 
allowing physicians to address two pathologies in one 
surgical intervention without cutting the conjunctiva. 
M.S. Berlin et al. 
ELT has been approved for use in the European Union 
and Switzerland since 1998. Thousands of ELT proce-
dures have been successful in lowering and maintaining 
lower IOP for years (Fig. 8.13). Currently, clinical studies 
are pending in both Canada and the United States. We 
Iook forward to a better future for our glaucoma patients 
and especially for their children. 
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